Tvardi Therapeutics (TVRD) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 9, 2026, with virtual participation available to shareholders.

• Shareholders of record as of April 14, 2026, are eligible to vote on key proposals.

Voting matters and shareholder proposals

• Election of three nominees—Imran Alibhai, Ph.D., Cynthia Smith, and Sujal Shah—as Class II directors to serve until the 2029 annual meeting.

• Advisory vote to approve the compensation of named executive officers.

• Advisory vote on the preferred frequency of future say-on-pay votes.

• Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.

• Proxies may vote on other business as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.

• Three nominees are presented for election as Class II directors with terms expiring in 2029.